جست‌وجوی استاد و پژوهشگر

Hai-Quan Maoمشاهده پروفایل

استاد

• Biomaterials
• Regenerative Engineering
• Therapeutic Delivery
• +۳ مورد دیگر

Hai-Quan Mao is a Professor of Materials Science and Engineering at Johns Hopkins University, with a joint appointment in the Biomedical Engineering Department (School of Medicine). He directs the Institute for NanoBioTechnology (INBT) and leads the Translational Tissue Engineering Center. His research focuses on biomaterials, regenerative engineering, and immunoengineering, particularly developing nanomaterials for therapeutic delivery and tissue regeneration. Mao holds 35 U.S. patents, co-founded two biotech companies, and received prestigious awards including National Academy of Inventors Fellow and NSF CAREER Award. Education: BS in Chemistry (1988) and PhD in Polymer Chemistry (1993) from Wuhan University. Postdoctoral training at Johns Hopkins (1995–1998), followed by roles at Johns Hopkins Singapore (1999–2003) before joining the Whiting School faculty. Research emphasizes nanofiber scaffolds for liver/nerve regeneration, DNA/lipid nanoparticle engineering for gene therapy, and artificial lymph node matrices for immunotherapy. His lab translates biomaterials innovations into clinical applications, with NIH-funded projects addressing cancer, malaria, and tissue damage. Awards include over 60 provisional patents, multiple Johns Hopkins translational awards, and Thalheimer Awards for research. He serves as associate editor of Biomaterials and editorial board member of major journals. Lab activities include scalable nanoparticle manufacturing, machine learning for material design, and collaborations with industry/clinical partners. Recent work includes lipid nanoparticle optimization for mRNA vaccines and exosome-based therapies for Crohn’s disease.

• Drug Delivery
• Nanomedicine
• Biopharmaceutics
• +۷ مورد دیگر

Dr. Shyh-Dar Li is a Professor and Tong Louie Chair in Pharmaceutical Sciences at the University of British Columbia's Faculty of Pharmaceutical Sciences, where he also serves as Chair of Nanomedicine and Chemical Biology. With a BSc in pharmacy from National Taiwan University (1998) and PhD in pharmaceutical sciences from UNC Chapel Hill (2008), followed by postdoctoral training at UC San Diego's Moores Cancer Center (2009), Dr. Li has established himself as a leading researcher in advanced drug delivery systems. His research focuses on developing innovative nanomedicine platforms for targeted delivery of biological therapeutics including peptides, proteins, antibodies, and nucleic acids. Dr. Li's laboratory has pioneered several novel drug delivery approaches, particularly in lipid-based nanoparticles, phospholipid-free vesicles, and polymer systems for cancer immunotherapy, pain management, and protein delivery. His work bridges fundamental nanotechnology with translational applications for difficult-to-treat diseases. Analysis of his recent publications reveals a strong emphasis on tumor microenvironment modulation, endosomal escape mechanisms for nucleic acid delivery, and non-invasive delivery routes for protein therapeutics. His research demonstrates increasing sophistication in nanocarrier engineering, with recent work incorporating machine learning approaches to optimize nanoparticle design and expanding into immunomodulatory therapies that harness the body's immune system to fight cancer. Scientific Recognition: 2014 AFPC New Investigator Award 2013 AAPS New Investigator Award in Pharmaceutics and Pharmaceutical Technologies 2013 CIHR New Investigator Award 2013 CSPS Early Career Award 2012 Prostate Cancer Foundation Young Investigator Award Dr. Li's research program has been consistently supported by major Canadian funding agencies including CIHR, NSERC, and MITACS. He actively collaborates across disciplines and accepts graduate students into his research program, focusing on cutting-edge approaches to overcome biological barriers in drug delivery. His laboratory, the Laboratory of Targeted Drug Delivery and Nanomedicine, serves as a hub for innovation in pharmaceutical nanotechnology.

Rotem Karniمشاهده پروفایل

دانشیار

• Alternative RNA Splicing
• RNA Biology
• Cancer Therapy
• +۴ مورد دیگر

Rotem Karni, PhD, is an Associate Professor of Genetics at the Perelman School of Medicine, University of Pennsylvania, Philadelphia. He leads a research lab focused on understanding how alternative RNA splicing contributes to cancer and genetic diseases, with a strong emphasis on translating these findings into RNA-based therapies. Karni's lab develops decoy oligonucleotides, small molecules, and splice-switching technologies to modulate splicing factors and enhance immunotherapy. Education BSc in Biological Chemistry from The Hebrew University of Jerusalem (1997) PhD in Biological Chemistry from The Hebrew University of Jerusalem, Israel (2002) Postdoctoral Fellowship at Cold Spring Harbor Laboratory, NY (2002-2007) Karni's research explores the deregulation of alternative splicing in oncogenesis, particularly how splicing factors like RBFOX2 and S6K1 influence metastasis, DNA repair, and immune checkpoint modulation. His team investigates m6A RNA modifications for stabilizing mutant genes, with applications in Duchenne Muscular Dystrophy and pancreatic cancer. The lab's work is commercialized through biotech companies: SKIP Therapeutics, Andlit Therapeutics, and RNAble. Selected Research Trends RNA mis-splicing and neoantigen generation (2025) Splicing factor inhibition for tumor suppression (2023) Metastatic splicing signatures in pancreatic cancer (2023) Immune checkpoint splicing in cancer immunotherapy (2021) m6A modulation for mRNA stabilization (2023) Advising & Collaborations Karni has mentored numerous PhD and postdoctoral researchers, many of whom now hold leadership roles in academia, biotech, and medical institutions globally. His lab collaborates extensively on projects involving RNA innovation, including partnerships with the Institute for RNA Innovation. Contact Department of Genetics & Institute for RNA Innovation, One uCity Square, Room 4018, Philadelphia, PA 19104 Phone: 215-898-5072 Email: Rotem.Karni@Upenn.edu

Kenneth Hoehnمشاهده پروفایل

استادیار

• Computational Immunology
• Evolutionary Biology
• B Cell Biology
• +۵ مورد دیگر

Kenneth Hoehn is an Assistant Professor in the Department of Biomedical Data Science at the Geisel School of Medicine, Dartmouth College. As a computational immunologist with expertise in evolutionary biology, he develops computational evolutionary approaches to trace cellular lineages, particularly B cells, in contexts such as infection, vaccination, cancer, and autoimmune diseases. His research focuses on understanding adaptive immunity in conditions like COVID-19 Food allergies Myasthenia gravis through collaborations with experimental teams. Key projects include: Phylogenetic modeling of B cell responses Evolutionary signatures in immune repertoires Tracking B cell dissemination in autoimmune diseases Epigenetic regulation of memory B cells Recent publications highlight trends in single-cell immunology , phylogenetic inference , and computational tools for analyzing B cell dynamics. His lab at Dartmouth integrates evolutionary genetics with high-resolution immune profiling.

• Immunology
• Virology
• Inflammation
• +۵ مورد دیگر

Santiago F. González is a Group Leader at the Institute for Research in Biomedicine (IRB) in Bellinzona, Switzerland, and an extraordinary professor at the University of Italian Switzerland (USI). He earned dual PhDs in microbiology (University of Santiago de Compostela, Spain) and immunology (University of Copenhagen, Denmark), followed by postdoctoral work (2007–2011) at Harvard Medical School's Immune Disease Institute under Michael Carroll. PhD in Microbiology, University of Santiago de Compostela PhD in Immunology, University of Copenhagen His research focuses on immune system dynamics during respiratory viral infections, vaccination, and cancer metastasis. Key areas include influenza recognition , lymph node inflammation , and immune cell behavior in vivo. He pioneered studies on C-type lectin receptors (e.g., SIGN-R1) in viral immunity and epigenetic modulators for inflammation. Recent publications highlight his work in epigenetic drug development , nanovaccines , and computational tools for immune cell tracking. His group uses two-photon intravital microscopy and spatial-temporal modeling to dissect immune responses. Scientific awards include three EU Marie Curie Fellowships (2004–2013), enabling his transition to independent research. His collaborations span Harvard, USI, and European institutions, with grants from the EU and Swiss research bodies. His lab at IRB, established via the 2013 Marie Curie Career Integration Grant , develops novel imaging approaches and therapeutic strategies for infectious and immune-mediated diseases.

• Tropical Medicine
• Travel Medicine
• Migrant Health
• +۳ مورد دیگر

Sapha Barkati, MD, MSc is an Assistant Professor at the Department of Medicine, Faculty of Medicine and Health Sciences, McGill University , and an Investigator at the RI-MUHC Glen site . Her work bridges clinical practice and research in tropical medicine, focusing on parasitic diseases affecting vulnerable populations. Affiliations: Assistant Professor, McGill University Investigator, Research Institute of the McGill University Health Centre (RI-MUHC) McGill International Tuberculosis Centre Research Focus: Specializes in neglected tropical diseases like strongyloidiasis and tegumentary leishmaniasis, particularly among migrants and immunocompromised individuals. Studies include: Physician awareness of Strongyloides screening Prevalence patterns in non-endemic countries HTLV-1 co-infection treatment response Cost-effective screening strategies Scientific Contributions: Key publications address tropical disease management in non-endemic settings, mpox outbreak dynamics, and SARS-CoV-2 immunity patterns. Her work emphasizes evidence-based guidelines for: Parasite screening in transplant recipients Leishmaniasis treatment protocols Traveler disease prevention Collaborative Networks: Partners with institutions like Universidad Peruana Cayetano Heredia and participates in GeoSentinel surveillance. Leads studies on: Covid-19 health disparities Vaccine effectiveness against variants Remote patient monitoring systems

Ali Gilles Tchenguise Miserezمشاهده پروفایل

استاد

• Biological Materials
• Biomimetics
• Bioinspired Materials
• +۷ مورد دیگر

Professor Ali Gilles Tchenguise Miserez holds a joint appointment as Professor in the School of Materials Science and Engineering and the School of Biological Sciences at Nanyang Technological University (NTU) in Singapore. He is also the President's Chair in Materials Science and Engineering. His research group, the Biological and Biomimetic Materials Laboratory (BBML), is highly interdisciplinary, bringing together molecular biologists, chemists, bio-physicists, and materials scientists to study natural materials with unique properties not found in man-made materials. Prof. Miserez's research interests span multiple areas including bioelastomeric membranes & coiled-coil engineering, mechanisms of biofouling adhesion & anti-adhesive coatings, molecular biomimetics of non-mineralized hard tissues, biomineralized structures with graded properties, and liquid-liquid phase separation. His work focuses on understanding the molecular, physico-chemical, and structural principles of biological materials and translating these designs into novel biomimetic synthesis strategies. His laboratory emphasizes "green chemistry" approaches that mimic nature's energy-efficient synthesis methods under ambient conditions. Prof. Miserez's publication record demonstrates significant impact across multiple disciplines, with work appearing in top journals including Science, Nature Materials, Nature Biotechnology, Nature Chemical Biology, and Advanced Materials. His recent research has particularly focused on peptide coacervates for intracellular delivery of therapeutics, with applications in cancer treatment, mRNA delivery, and nucleic acid therapeutics. This work represents a convergence of materials science, biochemistry, and medicine with significant translational potential. Singapore National Research Foundation (NRF) Fellowship (2011) - $3 Million individual research grant for early career scientists Prof. Miserez has mentored numerous PhD students and postdoctoral researchers, many of whom have gone on to successful careers in academia and industry. His laboratory has developed strong international collaborations and has secured significant research funding. Current projects include developing peptide-based delivery systems for cancer therapeutics, understanding marine biofouling mechanisms, and creating biomimetic materials inspired by natural systems. The BBML laboratory is actively recruiting talented researchers interested in interdisciplinary work at the interface of biology and materials science.

Theresa Raimondoمشاهده پروفایل

استادیار

• Biomaterials
• Drug Delivery
• RNA-based Therapeutics
• +۵ مورد دیگر

Theresa Raimondo is the Manning Assistant Professor of Engineering at Brown University, with a secondary appointment in the Division of Biology and Medicine. She joined the Brown Engineering faculty in January 2024 after completing her postdoctoral training at MIT's Koch Institute. Dr. Raimondo leads the Raimondo Research Lab, which focuses on chemically modifying RNA and designing nanoparticles for therapeutic delivery to the body, an immunotherapy concept that holds immense promise in the field of immunoengineering. Her educational background includes: PhD in Engineering Sciences – Bioengineering from Harvard University (2019) MEng from Harvard University (2019) Sc.B. in Chemical and Biochemical Engineering from Brown University (2011) Dr. Raimondo's research is broadly focused on the design of targeted drug-delivery vectors and novel RNA-based therapeutics for applications in cancer, immunotherapy, and tissue regeneration. Her work primarily centers on developing novel lipid nanoparticles (LNPs) for RNA-based therapies, contributing to adjuvanted mRNA-based vaccines and siRNA-based cancer immunotherapies. By optimizing LNP formulation and modulating RNA constructs, she seeks to understand how RNA-LNPs modulate immunity and develop new therapeutic approaches. Her expertise spans biomaterials, drug delivery, biomolecular engineering, nanomedicine, tissue engineering, and regenerative medicine. Analysis of Dr. Raimondo's recent publications reveals a strong focus on RNA delivery systems and lipid nanoparticle technology. Her work spans from fundamental studies on nanoparticle design to applications in cancer immunotherapy, vaccine development, and tissue regeneration. A significant portion of her research involves optimizing lipid formulations for improved mRNA delivery and exploring how these systems interact with the immune system. Her publications demonstrate a trajectory from basic biomaterials research to increasingly translational work with therapeutic applications. Dr. Raimondo has received numerous prestigious awards: 2025 NAE Symposium selection (Grainger Foundation Frontiers of Engineering) 2025 appointment to the inaugural Early Career Board of ACS Applied Bio Materials 2024 selection as MIT Faculty Founder Initiative finalist 2022 Convergence Scholar fellowship from MIT's Marble Center for Cancer Nanomedicine National Science Foundation graduate research fellowship Harvard's Smith family graduate fellowship Dr. Raimondo is actively involved in mentoring students through courses including ENGN 0931L - Biomedical Engineering Design and Innovation II, ENGN 1490 - Biomaterials, and ENGN 1931L - Biomedical Engineering Design and Innovation II. Her research program is supported by various grants, though specific funding sources aren't detailed in the provided text. The Raimondo Research Lab represents a dynamic environment where engineering principles are applied to solve complex biological challenges in drug delivery and regenerative medicine. The Raimondo Research Lab at Brown University serves as a hub for innovation in RNA delivery and biomaterials design. The lab brings together expertise in chemical engineering, molecular biology, and immunology to develop next-generation therapeutic platforms. Current research directions include optimizing lipid nanoparticle formulations, exploring novel RNA modifications, and investigating immune responses to RNA therapeutics across various disease contexts.

Hang Luمشاهده پروفایل

دانشیار

• Science Communication
• Health Communication
• Environmental Communication
• +۴ مورد دیگر

Hang Lu is an Associate Professor in the Department of Communication and Media at the University of Michigan's College of Literature, Science, and the Arts. He specializes in science, health, environmental, and risk communication (ComSHER), with a focus on media psychology. His research explores audience responses to media messages about sensitive topics and strategies to enhance message effectiveness. Lu holds a Ph.D. in Communication from Cornell University (2018), along with advanced degrees from Cornell, Marquette University, and Central South University in China. He directs the Media and Risk (MaR) Lab and previously served as a postdoctoral fellow at the Annenberg Public Policy Center. His research spans four main areas: 1) emotion dynamics in media responses, 2) predictors of information behaviors, 3) media effects on stigmatization, and 4) AI applications in sensitive domains. He has published in journals like Journal of Communication , Risk Analysis , and Public Understanding of Science , earning multiple top paper awards. As Vice Chair of the Environmental Communication Division at the International Communication Association, Lu contributes to interdisciplinary dialogue. His work addresses critical societal issues such as climate change communication, vaccination hesitancy, and emerging technology ethics.

Rajendra Kurapatiمشاهده پروفایل

استادیار

• Biodegradable Nanomaterials
• Nanomedicine
• Bioengineering
• +۵ مورد دیگر

Dr. Rajendra Kurapati is an Assistant Professor at the School of Chemistry , Indian Institute of Science Education and Research Thiruvananthapuram (IISER TVM) . His research focuses on biodegradable 2D materials for biomedical applications, addressing nanomaterial biopersistence issues through enzymatic degradation studies. He leads the Biomaterials Lab and collaborates with institutions across France, Ireland, Portugal, and the UK. Born in Andhra Pradesh, India B.Sc. & M.Sc. in Chemistry (Acharya Nagarjuna University, University of Hyderabad) Ph.D. in Materials Engineering (Indian Institute of Science, 2014) Postdoc: CNRS Strasbourg (2014-2017), CÚRAM Galway (2018-2020) His research explores 2D material-biopolymer hybrids for drug/gene delivery , nanotheranostics , and antimicrobial coatings . Key article trends include: Graphene/MoS2 biodegradation by human enzymes Antibacterial coatings for medical implants Microplastics' environmental impact Lipid nanoparticles for mRNA vaccines ZnO quantum dots for bioimaging Polymer multilayer drug delivery systems Major scientific awards : DBT Ramalingaswami Fellowship (INR 40 lakhs over 5 years) SERB Start-up Grant (32 lakhs over 2 years) SERB Special Grant (45 lakhs over 3 years) DBT Mission Innovation Grant (18 lakhs over 6 months) His academic contributions span 15+ high-impact publications in journals like Advanced Materials , Nanoscale , and Chemical Communications , covering topics from graphene biodegradation to antimicrobial coatings and bioimaging . 10+ alumni students have graduated from his lab, with placements at institutions including University of Strasbourg and Dublin City University.

Chengzhong (Michael) Yuمشاهده پروفایل

استاد پژوهشی

• Nanotechnology
• Materials Science
• Drug Delivery
• +۵ مورد دیگر

Professor Chengzhong (Michael) Yu is a Research Professor at the Australian Institute for Bioengineering and Nanotechnology (AIBN), University of Queensland. His research focuses on functional nanomaterials for healthcare, energy, and environmental applications. He holds over 400 publications with 36,000+ citations and has received prestigious awards like the NHMRC Leadership Fellowship and ARC Future Fellowship. Education: PhD in Chemistry from Fudan University. Research Interests: Silica-based nanoparticles for drug/gene delivery, energy storage materials (e.g., aluminum-ion batteries), sustainable catalysis, and nano-pesticides for agriculture. His group develops biomaterials for cancer therapy, immunotherapy, and mRNA vaccine platforms. Recent Trends in Publications: Focused on advancing nanocarrier systems for therapeutics, electrocatalytic H₂O₂ synthesis from seawater, and sustainable energy solutions. Collaborates with industry partners like N4 Pharma and Baosteel for translational applications. Awards & Grants: Multiple ARC Discovery/Linkage grants, NHMRC funding, and industry partnerships totaling millions. Notable projects include mRNA delivery platforms and rechargeable aluminum-ion batteries. Supervision & Labs: Mentors over 20 PhD/Master’s students. Leads the Yu Group, collaborating on projects like ‘Designer Nanoparticles for mRNA Factories’ and ‘Nanotechnology for Flystrike Control in Livestock’.

Cecilia Lealمشاهده پروفایل

استاد

• Soft Condensed Matter
• Biomaterials
• Drug Delivery
• +۵ مورد دیگر

Cecilia Leal is a Professor and Racheff Faculty Scholar in the Department of Materials Science and Engineering at the University of Illinois at Urbana-Champaign, with additional appointments at the Carle Illinois College of Medicine, Materials Research Laboratory, and Beckman Institute. Her interdisciplinary research program bridges materials science, biophysics, and medicine to develop innovative therapeutic delivery systems. Dr. Leal's research focuses on the self-organization of biomolecular systems, particularly lipid membranes, peptides, and nucleic acids. Her lab investigates how structural complexity of lipids and bio-membranes relates to disease mechanisms and informs the design of better gene and drug delivery systems. Key projects include developing lipid nanoparticles for mRNA delivery, studying polymer-lipid hybrid membranes, and characterizing lipid droplet dynamics in metabolic diseases. The lab employs advanced techniques including Small Angle X-ray Scattering, Cryo-EM, and live cell imaging. Her recent publications (2023-2025) reveal a strong emphasis on lipid-based delivery systems for mRNA therapeutics and cancer treatment, with particular attention to how nanostructure affects delivery efficiency. The research spans from fundamental biophysics of lipid-polymer interactions to applied therapeutic development, demonstrating consistent translation of basic science to medical applications. University of Illinois Provost's Distinguished Promotion to Full Professor Award (2024) University of Illinois Scholar (2023) NIH New Innovator Award (2016) NSF CAREER Award (2016) Racheff Faculty Scholar Award (2019) Dr. Leal has mentored numerous graduate students and postdocs, many now in prominent positions at MIT, Stanford, Dow Chemical, and pharmaceutical companies. Her research is supported by multiple NIH and NSF grants, and she maintains active collaborations with medical researchers studying obesity, cancer, and respiratory diseases. She teaches core courses including MSE 201 (Phases and Phase Relations) and MSE 473 (Biomolecular Materials Science), consistently earning excellent teaching ratings. The Leal Lab operates as an interdisciplinary team of materials scientists, physicists, and chemists using cutting-edge characterization tools to solve biomedical challenges. The lab's work on lipid nanoparticle structure has direct relevance to next-generation mRNA vaccines and cancer therapies, with several publications highlighted in C&EN News and other prominent scientific media.

Kelsey Swingleمشاهده پروفایل

استادیار

• Biomaterials Science
• Immune Engineering
• Reproductive Biology
• +۶ مورد دیگر

Kelsey Swingle is an Assistant Professor of Bioengineering at Rice University, where she leads the Swingle Lab at the intersection of biomaterials science, immune engineering, and reproductive biology. Her research focuses on engineering therapeutic and vaccine technologies with translational potential. Ph.D. in Bioengineering from the University of Pennsylvania B.S.E. in Biomedical Engineering from Case Western Reserve University Dr. Swingle’s research explores the design of lipid nanoparticles (LNPs) and nucleic acid therapeutics for women’s health applications, including pre-eclampsia, preterm birth, and gynecologic cancers. Her work integrates bioengineering principles with immune modulation strategies to develop targeted therapies. The trends in her publications highlight advancements in LNP elasticity optimization for placental mRNA delivery, targeted systemic RNA delivery to the brain, and in utero gene editing applications. Her lab prioritizes interdisciplinary approaches to overcome biological barriers in women’s health. 2025 Solomon R. Pollack Award for Excellence in Graduate Bioengineering Research 2024 Muriel Joan Drew Hege Award for Women in Cellular Immunotherapy Research 2024 Penn Engineering Outstanding Teaching Award 2023 Gordon Research Conference Travel Award 2022 Society for Biomaterials STAR Award 2020 NSF Graduate Research Fellowship The Swingle Lab collaborates with the Texas Medical Center to develop precision nanomedicines. Her team employs in vitro, ex vivo, and in vivo models to study biomaterial interactions with female-specific tissues, emphasizing translational research and inclusive scientific communication.

Ralph Bockمشاهده پروفایل

استاد

• Plant Molecular Biology
• Chloroplast Biology
• Organelle Biotechnology
• +۷ مورد دیگر

Prof. Dr. Ralph Bock serves as Director of Department 3: Organelle Biology, Biotechnology and Molecular Ecophysiology at the Max Planck Institute of Molecular Plant Physiology in Potsdam, Germany, where he also leads the Organelle Biology and Biotechnology research group. Previously, he held positions as C4 Professor for Plant Biochemistry and Biotechnology at the University of Münster (2001-2004) and Group Leader at the Institute of Biology III, University of Freiburg (1996-2001). His academic credentials include: Habilitation: University of Freiburg, 1999 Doctorate: University of Freiburg, 1996 Diploma: University of Halle, 1993 Prof. Bock's research focuses on plant molecular biology with particular emphasis on chloroplast biology, organelle biotechnology, and molecular ecophysiology. His work spans genetic engineering of plastids, photosynthesis research, plant biotechnology applications, and understanding organelle-nucleus communication. He has made significant contributions to developing chloroplast transformation systems and applying them to molecular farming, metabolic engineering, and understanding fundamental processes in plant cell biology. His research has important implications for sustainable agriculture, bioenergy, and pharmaceutical production, particularly through the development of plant-based systems for producing vaccines and therapeutic proteins. Analysis of Prof. Bock's recent publications (2023-2025) reveals a strong focus on chloroplast biology, genetic engineering, and molecular farming applications. His work spans fundamental research on organelle genetics, photosynthesis, and stress responses, as well as applied research on using plant and algal systems for biopharmaceutical production. A notable trend is the increasing use of advanced genetic engineering techniques, including CRISPR-based approaches, to manipulate organelle genomes. His research also shows growing interest in algal systems as alternative expression platforms for molecular farming, particularly red algae like Porphyridium for producing viral antigens and glycoproteins.

Kuo-Ching Meiمشاهده پروفایل

استادیار

• mRNA therapeutics
• lipid nanoparticles (LNPs)
• RNA delivery
• +۷ مورد دیگر

Kuo-Ching Mei is an Assistant Professor of Molecular Pharmaceutics in the College of Pharmacy at the University of Utah. His laboratory pioneers lipid nanoparticle (LNP)-based gene delivery platforms that span cancer immunotherapy, immune tolerance induction, and programmable nanomedicine. Education B.Sc., Taipei Medical University Ph.D., University of London Dr. Mei’s research integrates molecular pharmaceutics, immunoengineering, and translational pharmaceutical sciences to advance precision immunotherapies. Core themes include mRNA-LNP systems for both immunostimulatory (anti-cancer vaccines) and immunomodulatory (tolerogenic) applications, the influence of immunometabolic cues (IFN-γ, amino-acid deprivation) on RNA translation, and the development of next-generation lipid chemistries for organ- and cell-specific delivery. Across his recent publications, a clear trend emerges toward refining LNP composition and architecture to enhance RNA delivery specificity, minimize toxicity, and modulate innate and adaptive immunity. Studies range from fundamental formulation science to pre-clinical evaluation in syngeneic tumor models and assessments of anti-vector immune responses. Research Support & Collaborations While specific grant numbers are not listed, the breadth and continuity of projects—from programmable lipid synthesis to high-throughput in vivo screening—indicate robust funding and active interdisciplinary collaborations within the University of Utah’s bioscience ecosystem. Laboratory & Team Dr. Mei leads a dynamic lab that employs chemical synthesis, formulation development, high-throughput screening, and integrated in vitro/in vivo disease models to translate discoveries into clinically viable RNA therapeutics and immunoengineering solutions.